Geode Capital Management
DMAC icon

Geode Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Geode Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.39M Sell
893,827
-288
-0% -$2.01K ﹤0.01% 2647
2026
Q2 		$6.3M Buy
894,115
+113,599
+15% +$698K ﹤0.01% 2793
2026
Q1 		$5.29M Buy
780,516
+16,261
+2% +$129K ﹤0.01% 2706
2025
Q4 		$6.08M Buy
764,255
+52,437
+7% +$392K ﹤0.01% 2668
2025
Q3 		$4.89M Buy
711,818
+81,670
+13% +$443K ﹤0.01% 2792
2025
Q2 		$2.46M Buy
630,148
+314,407
+100% +$1.23M ﹤0.01% 3074
2025
Q1 		$1.2M Buy
315,741
+9,990
+3% +$57.1K ﹤0.01% 3243
2024
Q4 		$1.66M Sell
305,751
-1,207
-0.4% -$5.69K ﹤0.01% 3198
2024
Q3 		$1.29M Buy
306,958
+70,070
+30% +$259K ﹤0.01% 3266
2024
Q2 		$699K Sell
236,888
-2,347
-1% -$6.44K ﹤0.01% 3447
2024
Q1 		$663K Buy
239,235
+20,457
+9% +$59.4K ﹤0.01% 3515
2023
Q4 		$621K Hold
218,778
– – ﹤0.01% 3533
2023
Q3 		$565K Buy
218,778
+33,908
+18% +$109K ﹤0.01% 3555
2023
Q2 		$799K Hold
184,870
– – ﹤0.01% 3441
2023
Q1 		$283K Hold
184,870
– – ﹤0.01% 3887
2022
Q4 		$292K Sell
184,870
-349
-0.2% -$470 ﹤0.01% 3901
2022
Q3 		$229K Buy
185,219
+8,197
+5% +$12.8K ﹤0.01% 4125
2022
Q2 		$357K Buy
177,022
+2,164
+1% +$5.05K ﹤0.01% 3943
2022
Q1 		$437K Buy
174,858
+7,095
+4% +$20.1K ﹤0.01% 4003
2021
Q4 		$625K Hold
167,763
– – ﹤0.01% 3931
2021
Q3 		$672K Buy
167,763
+34,194
+26% +$131K ﹤0.01% 3886
2021
Q2 		$594K Buy
133,569
+5,101
+4% +$41.8K ﹤0.01% 3859
2021
Q1 		$1.18M Buy
128,468
+24,769
+24% +$231K ﹤0.01% 3482
2020
Q4 		$1.05M Buy
103,699
+41,037
+65% +$225K ﹤0.01% 3355
2020
Q3 		$265K Buy
62,662
+6,250
+11% +$33.1K ﹤0.01% 3629
2020
Q2 		$390K Sell
56,412
-1,112
-2% -$4.96K ﹤0.01% 3457
2020
Q1 		$161K Buy
57,524
+39,967
+228% +$165K ﹤0.01% 3618
2019
Q4 		$85K Buy
17,557
+2,158
+14% +$6.72K ﹤0.01% 3999
2019
Q3 		$31K Buy
+15,399
New +$49.8K ﹤0.01% 4109

Other funds holding DMAC

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Bleichroeder LP
Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Cobalt Capital Management
Cobalt Capital Management Short Hills, New Jersey $174M AUM 39.41% 1-Year Est. Return

Geode Capital Management's DMAC Position: Q3 2026 in Review

Geode Capital Management reduced its DiaMedica Therapeutics (DMAC) stake by 0.03% in Q3 2026, selling an estimated $2.01K and leaving 893,827 shares worth $7.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2647.

Geode Capital Management first reported a position in DMAC in Q3 2019 and has held it in 29 quarters since. 67 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • Geode Capital Management held 893,827 shares of DiaMedica Therapeutics worth $7.39M as of Q3 2026.
  • Geode Capital Management sold 288 DiaMedica Therapeutics shares in Q3 2026, an estimated $2.01K.
  • DiaMedica Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2647 holding.
  • Geode Capital Management first reported a position in DiaMedica Therapeutics in Q3 2019 and has held it in 29 quarters since.
  • 67 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.